New pill could help restore skin color in vitiligo patients
NCT ID NCT07625891
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if the drug safely helps bring back skin color, especially on the face.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
D-2570 (an oral drug taken as a pill once daily)
What this could lead to
If successful, this could point toward a new daily pill treatment to help restore skin color in people with vitiligo.
What could go wrong
This is an early Phase 2 trial with only 160 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 201203, China
Contact Phone: •••-•••-•••• Email: •••••@•••••